Augmedics successfully closed an $82.5 million Series D financing. The news comes the same week the company marks its record 4,000th US patient treated with the xvision Spine System, which uses augmented reality (AR) to give surgeons “x-ray vision” during surgery.
The funds will support Augmedics’ rapidly expanding US commercial footprint as well as the delivery of next-generation platform advancements which will enable mass-scale adoption of the xvision technology.
The vision system was granted FDA 510(k) marketing clearance in late 2019 and is reported to be the first FDA-cleared AR navigation system for surgery. The technology superimposes critical data onto the surgical field, allowing surgeons to visualize patient anatomy through skin and tissue and to accurately navigate instruments and implants during spine surgery. xvision allows surgeons to keep their eyes directly on the patient for better visualization, control and accuracy during spine procedures.
Augmedics launched a significant platform expansion in March 2023, including the system’s first artificial intelligence (AI) application, laying the groundwork for future platform developments further supported by the financing.
“To close an $82.5 million round in the current fundraising environment is a testament to the dramatic impact Augmedics is making on the field of spine surgery. The accomplishment is underscored by the tremendous achievement of 4,000 patient lives impacted,” said Augmedics President & CEO Kevin Hykes. “We are pleased to secure the resources to continue leading the market in the adoption of augmented reality spine surgery.”
Augmedics successfully closed an $82.5 million Series D financing. The news comes the same week the company marks its record 4,000th US patient treated with the xvision Spine System, which uses augmented reality (AR) to give surgeons “x-ray vision” during surgery.
The funds will support Augmedics’ rapidly expanding US commercial footprint as...
Augmedics successfully closed an $82.5 million Series D financing. The news comes the same week the company marks its record 4,000th US patient treated with the xvision Spine System, which uses augmented reality (AR) to give surgeons “x-ray vision” during surgery.
The funds will support Augmedics’ rapidly expanding US commercial footprint as well as the delivery of next-generation platform advancements which will enable mass-scale adoption of the xvision technology.
The vision system was granted FDA 510(k) marketing clearance in late 2019 and is reported to be the first FDA-cleared AR navigation system for surgery. The technology superimposes critical data onto the surgical field, allowing surgeons to visualize patient anatomy through skin and tissue and to accurately navigate instruments and implants during spine surgery. xvision allows surgeons to keep their eyes directly on the patient for better visualization, control and accuracy during spine procedures.
Augmedics launched a significant platform expansion in March 2023, including the system’s first artificial intelligence (AI) application, laying the groundwork for future platform developments further supported by the financing.
“To close an $82.5 million round in the current fundraising environment is a testament to the dramatic impact Augmedics is making on the field of spine surgery. The accomplishment is underscored by the tremendous achievement of 4,000 patient lives impacted,” said Augmedics President & CEO Kevin Hykes. “We are pleased to secure the resources to continue leading the market in the adoption of augmented reality spine surgery.”
Copy to clipboard 
